Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 10 years
- Director since
- 2023
10 years of board service in total across 3 boards, counting each seat separately. Longest: Halozyme Therapeutics Inc., 3 years.
Halozyme Therapeutics Inc.
Director
Sutro Biopharma Inc.
Director
Artelo Biosciences Inc.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Sutro Biopharma Inc. June 5, 202685.7%
-
Artelo Biosciences Inc. January 30, 202666.3%
-
Artelo Biosciences Inc. June 30, 202387.7%
-
Sutro Biopharma Inc. June 8, 202359.9%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 15, 2025 | Sutro Biopharma Inc. | Open-market purchase | +50,000 | $0.80 | $40,000 |
| Nov 29, 2024 | Halozyme Therapeutics Inc. | Gift | −10,470 | — | — |
| Apr 25, 2024 | Halozyme Therapeutics Inc. | Grant or award | +6,501 | — | — |
| May 5, 2023 | Halozyme Therapeutics Inc. | Grant or award | +8,065 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.